Pathology

由卡尔·莫里森博士(GN)指导的RPCI病理资源网络(PRN)共享资源， 通过6个综合设施提供涉及生物检疫所有方面的专门技术、服务和专业知识：1)组织采购，2)病理学核心设施，3)石蜡档案，4)特殊 功能实验室，5)相关科学病理办公室(CSPO)，6)白血病银行。这 集中所有方面的生物制剂研究提供了稳定性、可靠性、成本效益和 质量控制。PRN利用最先进的实验室信息管理系统(LIMS)来 有效管理组织资源，并保持最高标准的质量控制。34个全职 PRN的教职员工(由CCSG基金资助的7名工作人员)提供关键服务，包括：组织 采购(医学博士领导和5名工作人员)；最先进的研究组织学(博士领导和5名工作人员)； 福尔马林固定石蜡包埋(FFPE)组织的档案管理和维护(2名工作人员)；特别 实验室职能，包括图像扫描和分析(1名博士领导)；组织微阵列(TMA)(1 激光显微解剖(1名工作人员)；大分子加工(1名工作人员)；光谱核型分析(1名博士学位 领导，1名工作人员；生物素临床试验支持(RN领导和5名工作人员)；白血病银行(MD 领导力，3名工作人员)。一些员工在多个领域担任职务。 自上次CCSG提交以来，(CSPO)是新的，并为以下需求提供了有效的解决方案 临床研究中的生物制品及相关科学。PRN为更多的人提供组织生物制品 每年有超过25项临床试验，几乎所有的干预性研究都有血液。PRN提供 集中设备，包括：免疫组织化学自动标记仪、冰冻组织冷冻器、冷冻箱报警器 和管理系统、Aperio图像扫描扫描、图像分析软件、Arcturus和徕卡 组织显微切割平台。所有这些都是由复杂的数百万美元的LIMS管理的。 在RPCI处对组织的访问是由各种疾病现场研究小组(DSRGs)决定的，但 总体指南由组织利用委员会(TUC)根据CCSG指南制定。 PRN向多个同行审查资助的调查员提供服务，并为以下方面作出重大贡献 癌症基因组图谱[PI：Carl Morison(GN)博士]。 第一优先使用由同行审查资助的RPCCCSG成员；第二优先使用非同行审查-- 资助的CCSG成员；第三优先考虑非成员和学术合作者；最后优先考虑 外部用户。在本报告所述期间，PRN共享资源为6名成员中的85名成员提供了服务 研究项目，CCSG成员使用同行评审资金的利用率为48%。CCSG制定了 增加了整个拟议预算的9%。

The RPCI Pathology Resource Network (PRN) Shared Resource, directed by Dr. Carl Morrison (GN), provides specialized technologies, services, and expertise involving all aspects of biospecimens through 6 integrated facilities: 1) Tissue Procurement, 2) Pathology Core Facility, 3) Paraffin Archive, 4) Special Functions Laboratory, 5) Correlative Science Pathology Office (CSPO), and 6) Leukemia Bank. This centralization of all aspects of biospecimen research provides stability, reliability, cost-effectiveness, and quality control. The PRN utilizes a state-of-the-art Laboratory Information Management System (LIMS) to effectively manage tissue resources, and maintains the highest standards of quality control. The 34 full time faculty and staff (7 staff supported by CCSG funding) in the PRN provide key services, including: tissue procurement (MD leadership and 5 staff); state-of-the-art research histology (PhD leadership and 5 staff); archive curation and maintenance of formalin fixed paraffin-embedded (FFPE) tissue (2 staff); special laboratory functions including image scanning and analysis (1 PhD leader); tissue microarray (TMA) (1 staff); laser microdissection (1 staff); macromolecule processing (1 staff); spectral karyotyping (1 PhD leader, 1 staff; biospecimen clinical trials support (RN leadership and 5 staff); leukemia banking (MD leadership, 3 staff). Some staff have roles in more than one area. The (CSPO) is new since the last CCSG submission and provides an effective solution to the need for biospecimens and correlative science in clinical research. The PRN provides tissue biospecimens to more than 25 clinical trials on an annual basis and blood to almost all interventional studies. The PRN provides centralized equipment, including: immunohistochemistry autostainers, frozen tissue cryostats, freezer alarms and management systems, Aperio image scanning ScanScope, image analysis software, Arcturus and Leica tissue microdissection platforms. All of these are managed by the sophisticated multi-million dollar LIMS. Access to tissues at RPCI is determined by the various Disease Site Research Groups (DSRGs), but the overall guidelines are set by the Tissue Utilization Committee (TUC), in accordance with CCSG guidelines. The PRN provides services to multiple peer-review funded investigators and provides major contributions to The Cancer Genome Atlas [PI: Dr. Carl Morrison (GN)]. First priority for use is given to peer-review-funded RPCI CCSG members; second priority to non-peer-review- funded CCSG members; third priority to non-members and academic collaborators; and last priority to external users. During the reporting period, the PRN shared resource has served 85 members from 6 research programs, with 48% utilization by CCSG members with peer reviewed funding. The CCSG makes up 9% of the overall proposed budget.